Trial Profile
Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Iniparib (Primary) ; Paclitaxel
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms SOLTI-NEOPARP
- Sponsors Sanofi
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 17 Mar 2017 This trial has been completed in Spain.
- 05 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Feb 2017 as reported by ClinicalTrials.gov.